Handel DiaMedica Therapeutics Inc. - DMAC CFD
Føj til favorit- Opsummering
- Historisk Data
- Begivenheder
- Resultatopgørelse
- Saldo
- Cash flow
- Ejerskab
Handelsbetingelser
| Spænd | 0.1506 | ||||||||
|
Long position, gebyr natten over
Long position overnight fee
Gå til platform | -0.024068% | ||||||||
|
Short position, gebyr natten over
Short position overnight fee
Gå til platform | 0.001846% | ||||||||
| Gebyr natten over, tid | 21:00 (UTC) | ||||||||
| Min. handlet mængde | 1 | ||||||||
| Valuta | USD | ||||||||
| Margen | 20% | ||||||||
| Aktiebørs | United States of America | ||||||||
| Kommission på handel | 0% |
*Information provided by Capital.com
Nøglestatistikker
| Tidligere luk* | 1.6729 |
| Åben* | 1.5739 |
| 1-Års Ændring* | -40.61% |
| Dagens Spænd* | 1.5458 - 1.6632 |
| 52-Ugers Spænd | 1.12-3.06 |
| Gennemsnitlig Volumen (10 dage) | 26.19K |
| Gennemsnitlig Volumen (3 måneder) | 827.55K |
| Market Cap | 45.48M |
| P/E-forhold | -100.00K |
| Udestående aktier | 26.44M |
| Omsætning | N/A |
| EPS | -0.50 |
| Dividend (Udbytte %) | N/A |
| Beta | 1.76 |
| Næste indtjeningsopgørelse | Mar 28, 2023 |
Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Luk | Change | Change (%) | Åben | High | Low |
|---|---|---|---|---|---|---|
| Mar 22, 2023 | 1.5458 | -0.0479 | -3.01% | 1.5937 | 1.6633 | 1.5454 |
| Mar 21, 2023 | 1.6729 | -0.0391 | -2.28% | 1.7120 | 1.7122 | 1.5843 |
| Mar 20, 2023 | 1.6925 | -0.0382 | -2.21% | 1.7307 | 1.7314 | 1.6529 |
| Mar 17, 2023 | 1.7316 | -0.0188 | -1.07% | 1.7504 | 1.7505 | 1.7010 |
| Mar 16, 2023 | 1.8296 | 0.0891 | 5.12% | 1.7405 | 1.8394 | 1.7405 |
| Mar 15, 2023 | 1.6923 | -0.0383 | -2.21% | 1.7306 | 1.7416 | 1.6820 |
| Mar 14, 2023 | 1.7805 | 0.0878 | 5.19% | 1.6927 | 1.8297 | 1.6422 |
| Mar 13, 2023 | 1.6922 | 0.1276 | 8.16% | 1.5646 | 1.7221 | 1.5646 |
| Mar 10, 2023 | 1.6531 | -0.0182 | -1.09% | 1.6713 | 1.7019 | 1.5645 |
| Mar 9, 2023 | 1.6923 | 0.0502 | 3.06% | 1.6421 | 1.7707 | 1.6421 |
| Mar 8, 2023 | 1.7709 | 0.0994 | 5.95% | 1.6715 | 1.7906 | 1.6715 |
| Mar 7, 2023 | 1.7219 | 0.0798 | 4.86% | 1.6421 | 1.7221 | 1.6421 |
| Mar 6, 2023 | 1.7020 | -0.0188 | -1.09% | 1.7208 | 1.7612 | 1.6723 |
| Mar 3, 2023 | 1.7316 | 0.0790 | 4.78% | 1.6526 | 1.7514 | 1.6526 |
| Mar 2, 2023 | 1.7414 | 0.0300 | 1.75% | 1.7114 | 1.7612 | 1.7114 |
| Mar 1, 2023 | 1.7315 | -0.0294 | -1.67% | 1.7609 | 1.7609 | 1.6428 |
| Feb 28, 2023 | 1.6923 | 0.0502 | 3.06% | 1.6421 | 1.7416 | 1.6421 |
| Feb 27, 2023 | 1.6535 | 0.0099 | 0.60% | 1.6436 | 1.7024 | 1.5842 |
| Feb 24, 2023 | 1.6729 | 0.0297 | 1.81% | 1.6432 | 1.6828 | 1.6333 |
| Feb 23, 2023 | 1.6925 | -0.0089 | -0.52% | 1.7014 | 1.7604 | 1.6822 |
DiaMedica Therapeutics Inc. Events
| Tid (UTC) (UTC) | Land | Begivenhed |
|---|---|---|
| No events scheduled | ||
- Årlig
- Pr kvartal
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Total omsætning | 0 | 0 | 0 | 0.5 | 0 |
| Totale Driftsudgifter | 13.646 | 12.699 | 11.593 | 7.261 | 4.519 |
| Salgs/Generelle/Admin. Udgifter, Total | 4.881 | 4.389 | 3.693 | 2.739 | 1.313 |
| Forskning & Udvikling | 8.765 | 8.31 | 7.9 | 4.522 | 3.206 |
| Depreciation / Amortization | |||||
| Driftsindtægter | -13.646 | -12.699 | -11.593 | -6.761 | -4.519 |
| Renteindkomst (Udgift), Netto Ikke-Drift | 0 | -0.039 | 0.009 | ||
| Andre, Netto | 0.082 | 0.434 | 0.975 | 1.146 | 0.25 |
| Netto Indkomst Før Skat | -13.564 | -12.265 | -10.618 | -5.654 | -4.26 |
| Netto Indkomst Efter Skat | -13.592 | -12.292 | -10.649 | -5.734 | -4.26 |
| Netto Indkomst Før Ekstra Ting | -13.592 | -12.292 | -10.649 | -5.734 | -4.26 |
| Netto Indkomst | -13.592 | -12.292 | -10.649 | -5.734 | -4.26 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -13.592 | -12.292 | -10.649 | -5.734 | -4.26 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -13.592 | -12.292 | -10.649 | -5.734 | -4.26 |
| Fortyndet Netto Indkomst | -13.592 | -12.292 | -10.649 | -5.734 | -4.26 |
| Fortyndet Vægtet Gennemsnit Aktier | 20.7734 | 15.6803 | 11.9877 | 7.74352 | 5.93579 |
| Fortyndet EPS Uden Ekstraordinære Ting | -0.6543 | -0.78391 | -0.88833 | -0.74049 | -0.71768 |
| Fortyndet Normaliseret EPS | -0.6543 | -0.78391 | -0.88833 | -0.74049 | -0.71768 |
| Omsætning | 0 | 0.5 | 0 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total omsætning | 0 | 0 | 0 | 0 | 0 |
| Totale Driftsudgifter | 3.536 | 3.246 | 3.416 | 3.365 | 3.619 |
| Salgs/Generelle/Admin. Udgifter, Total | 1.562 | 1.375 | 1.084 | 1.209 | 1.213 |
| Forskning & Udvikling | 1.974 | 1.871 | 2.332 | 2.156 | 2.406 |
| Driftsindtægter | -3.536 | -3.246 | -3.416 | -3.365 | -3.619 |
| Andre, Netto | 0.035 | 0.007 | -0.027 | 0.098 | 0.004 |
| Netto Indkomst Før Skat | -3.501 | -3.239 | -3.443 | -3.267 | -3.615 |
| Netto Indkomst Efter Skat | -3.508 | -3.246 | -3.45 | -3.274 | -3.622 |
| Netto Indkomst Før Ekstra Ting | -3.508 | -3.246 | -3.45 | -3.274 | -3.622 |
| Netto Indkomst | -3.508 | -3.246 | -3.45 | -3.274 | -3.622 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -3.508 | -3.246 | -3.45 | -3.274 | -3.622 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -3.508 | -3.246 | -3.45 | -3.274 | -3.622 |
| Fortyndet Netto Indkomst | -3.508 | -3.246 | -3.45 | -3.274 | -3.622 |
| Fortyndet Vægtet Gennemsnit Aktier | 26.4431 | 26.5021 | 19.0357 | 18.7862 | 18.7667 |
| Fortyndet EPS Uden Ekstraordinære Ting | -0.13266 | -0.12248 | -0.18124 | -0.17428 | -0.193 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Fortyndet Normaliseret EPS | -0.13266 | -0.12248 | -0.18124 | -0.17428 | -0.193 |
- Årlig
- Pr kvartal
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Totale Nuværende Aktiver | 45.439 | 27.921 | 8.836 | 17.972 | 1.494 |
| Likvider og Kortsigtede Investeringer | 45.112 | 27.507 | 7.878 | 16.823 | 1.353 |
| Cash | 4.707 | 7.409 | 3.883 | 16.823 | 1.353 |
| Totale Tilgodehavender, Netto | 0.13 | 0.34 | 0.823 | 0.78 | 0.08 |
| Prepaid Expenses | 0.084 | 0.064 | 0.047 | 0.369 | 0.061 |
| Total Assets | 45.551 | 28.095 | 9.053 | 18.339 | 1.802 |
| Property/Plant/Equipment, Total - Net | 0.112 | 0.174 | 0.217 | 0.096 | 0.037 |
| Property/Plant/Equipment, Total - Gross | 0.179 | 0.231 | 0.26 | ||
| Accumulated Depreciation, Total | -0.067 | -0.057 | -0.043 | ||
| Total Current Liabilities | 1.524 | 2.028 | 1.318 | 1.296 | 1.003 |
| Accounts Payable | 0.509 | 1.099 | 0.182 | ||
| Accrued Expenses | 1.011 | 0.923 | 1.13 | ||
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0 | 0.084 | |||
| Total Liabilities | 1.527 | 2.081 | 1.436 | 1.314 | 1.003 |
| Total Long Term Debt | 0.003 | 0.007 | 0.013 | 0.018 | 0 |
| Other Liabilities, Total | 0 | 0.046 | 0.105 | ||
| Total Equity | 44.024 | 26.014 | 7.617 | 17.025 | 0.799 |
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Additional Paid-In Capital | 126.576 | 94.925 | 64.232 | 62.993 | 41.033 |
| Retained Earnings (Accumulated Deficit) | -82.501 | -68.909 | -56.617 | -45.968 | -40.234 |
| Other Equity, Total | -0.051 | -0.002 | 0.002 | ||
| Total Liabilities & Shareholders’ Equity | 45.551 | 28.095 | 9.053 | 18.339 | 1.802 |
| Total Common Shares Outstanding | 26.4431 | 18.7462 | 12.0069 | 11.9569 | 6.37066 |
| Accounts Receivable - Trade, Net | 0.13 | 0.78 | 0.08 | ||
| Other Long Term Assets, Total | 0 | 0.271 | 0.271 | ||
| Payable/Accrued | 1.291 | 0.919 | |||
| Current Port. of LT Debt/Capital Leases | 0.004 | 0.006 | 0.006 | 0.005 | 0 |
| Capital Lease Obligations | 0.003 | 0.007 | 0.013 | 0.018 | 0 |
| Kortsigtede Investeringer | 40.405 | 20.098 | 3.995 | ||
| Other Current Assets, Total | 0.113 | 0.01 | 0.088 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Totale Nuværende Aktiver | 42.111 | 45.439 | 48.537 | 21.629 | 24.195 |
| Likvider og Kortsigtede Investeringer | 41.047 | 45.112 | 48.097 | 21.295 | 23.401 |
| Cash | 3.032 | 4.707 | 16.219 | 2.228 | 3.329 |
| Kortsigtede Investeringer | 38.015 | 40.405 | 31.878 | 19.067 | 20.072 |
| Totale Tilgodehavender, Netto | 0.168 | 0.13 | 0.104 | 0.016 | 0.337 |
| Prepaid Expenses | 0.793 | 0.084 | 0.336 | 0.318 | 0.457 |
| Total Assets | 42.211 | 45.551 | 48.664 | 21.774 | 24.356 |
| Property/Plant/Equipment, Total - Net | 0.1 | 0.112 | 0.127 | 0.145 | 0.161 |
| Property/Plant/Equipment, Total - Gross | 0.162 | 0.179 | 0.187 | 0.199 | 0.209 |
| Accumulated Depreciation, Total | -0.062 | -0.067 | -0.06 | -0.054 | -0.048 |
| Total Current Liabilities | 1.434 | 1.524 | 1.624 | 1.44 | 1.178 |
| Accounts Payable | 0.433 | 0.509 | 0.699 | 0.239 | 0.689 |
| Accrued Expenses | 0.995 | 1.011 | 0.921 | 1.196 | 0.483 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.006 | 0.004 | 0.004 | 0.005 | 0.006 |
| Total Liabilities | 1.443 | 1.527 | 1.628 | 1.456 | 1.211 |
| Total Long Term Debt | 0.009 | 0.003 | 0.004 | 0.005 | 0.005 |
| Capital Lease Obligations | 0.009 | 0.003 | 0.004 | 0.005 | 0.005 |
| Other Liabilities, Total | 0 | 0 | 0.011 | 0.028 | |
| Total Equity | 40.768 | 44.024 | 47.036 | 20.318 | 23.145 |
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Additional Paid-In Capital | 126.884 | 126.576 | 126.296 | 96.126 | 95.68 |
| Retained Earnings (Accumulated Deficit) | -86.009 | -82.501 | -79.255 | -75.805 | -72.531 |
| Other Equity, Total | -0.107 | -0.051 | -0.005 | -0.003 | -0.004 |
| Total Liabilities & Shareholders’ Equity | 42.211 | 45.551 | 48.664 | 21.774 | 24.356 |
| Total Common Shares Outstanding | 26.4431 | 26.4431 | 26.4392 | 18.7862 | 18.7862 |
| Accounts Receivable - Trade, Net | 0.166 | 0.13 | |||
| Other Current Assets, Total | 0.103 | 0.113 |
- Årlig
- Pr kvartal
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Netto indkomst/Startlinje | -13.592 | -12.292 | -10.649 | -5.734 | -4.26 |
| Likvider Fra Driftsaktiviteter | -12.252 | -9.185 | -9.102 | -5.696 | -3.9 |
| Likvider Fra Driftsaktiviteter | 0.024 | 0.021 | 0.021 | 0.015 | 0.004 |
| Ikke-Likvide Ting | 1.777 | 1.891 | 1.139 | 0.659 | 0.4 |
| Likvid Rente Betalt | 0.002 | 0.002 | |||
| Ændringer i Driftskapital | -0.461 | 1.195 | 0.387 | -0.636 | -0.044 |
| Likvider fra Investeringsaktiviteter | -20.537 | -16.134 | -3.908 | -0.05 | -0.022 |
| Kapitaludgifter | -0.022 | -0.047 | -0.002 | -0.05 | -0.022 |
| Likvider fra Financieringsaktiviteter | 30.087 | 28.845 | 0.07 | 21.216 | 3.539 |
| Udstedelse (Pensionering) af Aktier, Netto | 30.093 | 28.85 | 0.075 | 21.216 | 3.539 |
| Udenlandsk Børs Effekter | |||||
| Netto Ændring i Likviditet | -2.702 | 3.526 | -12.94 | 15.47 | -0.383 |
| Cash Taxes Paid | 0.028 | 0.036 | 0.026 | ||
| Andre Investerings-Cash-Flow-Ting, Total | -20.515 | -16.087 | -3.906 | ||
| Udstedelse (Pensionering) af Gæld, Netto | -0.006 | -0.005 | -0.005 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -3.508 | -13.592 | -10.346 | -6.896 | -3.622 |
| Cash From Operating Activities | -3.888 | -12.252 | -9.448 | -6.402 | -4.313 |
| Cash From Operating Activities | 0.006 | 0.024 | 0.018 | 0.012 | 0.006 |
| Non-Cash Items | 0.443 | 1.777 | 1.354 | 1.023 | 0.551 |
| Changes in Working Capital | -0.829 | -0.461 | -0.474 | -0.541 | -1.248 |
| Cash From Investing Activities | 2.214 | -20.537 | -11.848 | 0.98 | -0.009 |
| Capital Expenditures | 0 | -0.022 | -0.015 | -0.013 | -0.009 |
| Other Investing Cash Flow Items, Total | 2.214 | -20.515 | -11.833 | 0.993 | 0 |
| Cash From Financing Activities | -0.001 | 30.087 | 30.106 | 0.241 | 0.242 |
| Issuance (Retirement) of Stock, Net | 0 | 30.093 | 30.111 | 0.244 | 0.244 |
| Issuance (Retirement) of Debt, Net | -0.001 | -0.006 | -0.005 | -0.003 | -0.002 |
| Net Change in Cash | -1.675 | -2.702 | 8.81 | -5.181 | -4.08 |
| Investornavn | Investortype | Procent udestående | Aktiebeholdning | Aktieændring | Beholdningsdato | IOmsætningsscore |
|---|---|---|---|---|---|---|
| EQT Partners AB | Private Equity | 10.8 | 2855847 | 304827 | 2022-07-08 | LOW |
| Trill AB,LLC. | Corporation | 9.6472 | 2551020 | 2551020 | 2021-09-28 | |
| Jacinto (Richard II) | Individual Investor | 9.4543 | 2500000 | 850947 | 2022-12-31 | LOW |
| Lytton (Laurence W) | Individual Investor | 4.0539 | 1071970 | -308296 | 2021-12-31 | MED |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.961 | 782989 | 349 | 2022-12-31 | LOW |
| Giuffre (Randall Michael) | Individual Investor | 1.4983 | 396184 | 35130 | 2023-01-03 | LOW |
| Omega Advisors, Inc. | Investment Advisor | 1.1345 | 300000 | 100000 | 2021-12-31 | LOW |
| Jacob Asset Management of New York, LLC | Investment Advisor | 0.8839 | 233730 | -4770 | 2022-12-31 | LOW |
| Pilnik (Richard D) | Individual Investor | 0.7937 | 209882 | 55555 | 2023-01-03 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.6991 | 184870 | -349 | 2022-12-31 | LOW |
| Lynch (Timothy Patrick) | Individual Investor | 0.3792 | 100259 | -100000 | 2022-12-31 | LOW |
| Burroughs (Amy Louise) | Individual Investor | 0.2772 | 73288 | 17156 | 2023-01-03 | LOW |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.2723 | 72012 | 2814 | 2022-12-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.252 | 66629 | 0 | 2022-12-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.2496 | 65997 | 1067 | 2022-12-31 | LOW |
| Pauls (Dietrich John) | Individual Investor | 0.211 | 55804 | 20000 | 2022-11-16 | |
| Morgan Stanley & Co. LLC | Research Firm | 0.1672 | 44201 | 2194 | 2022-12-31 | MED |
| Alcorn Harry W Jr | Individual Investor | 0.1663 | 43981 | 399 | 2022-03-22 | MED |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.1612 | 42634 | 0 | 2022-12-31 | LOW |
| Citadel Advisors LLC | Hedge Fund | 0.1483 | 39216 | 4304 | 2022-12-31 | HIGH |
Hvorfor vælge Capital.com? Vores tal taler for sig selv.
Capital.com Group500K+
Handlende
92K+
Månedlkige, aktive klienter
$53M+
Månedlig investeringsvolumen
$30M+
Hævet hver måned
Handelslommeregner
Udregn dit hypotetiske P&L hvis du havde åbnet en CFD-handel på en given dato (vælg en dato) og lukket den på en anden dato (vælg en dato).
Handelskurtage
0
- 1:1
Gearing
1:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Handelsstørrelse (Gearing x Investering):
Åben
Luk
Short Long
DiaMedica Therapeutics Inc. Company profile
Om DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. er en biofarmaceutisk virksomhed i den kliniske fase. Virksomheden fokuserer på at udvikle behandlinger for neurologiske og nyresygdomme, såsom akut iskæmisk slagtilfælde (AIS) og kronisk nyresygdom (CKD). Virksomhedens hovedprodukt DM199 efterligner opførslen af naturligt forekommende humane KLK1-proteiner for at bevare og genoprette cirkulationen i væv, der er beskadiget efter et slagtilfælde, og forbedre den generelle nyrefunktion. KLK1 er en serinprotease, eller et protein, der primært produceres i nyrerne, bugspytkirtlen og spytkirtlerne. DM199-behandling har potentiale til at forbedre cirkulationen og den overordnede funktion af kritiske systemer samt reducere inflammation og oxidativt stress. Virksomheden har også andre produkter i pipeline for IgA nefropati og afroamerikanere med CKD.
| Industry: | Bio Therapeutic Drugs |
301 Carlson Parkway
Suite 210
MINNEAPOLIS
MINNESOTA 55305
US
Resultatopgørelse
- Annual
- Quarterly
Folk ser også
Leder du stadig efter en mægler, du kan stole på?
Deltag sammen med 500.000+ handlende over hele verden, der valgte at handle hos Capital.com